As per nasdaq there's 6.5 million shares on short, if at all there's some good news from SIGA, it triggers short squeeze
Sentiment: Strong Buy
BX trading today ex-dividend of 0.43 cents, that's why its showing BX is UP by few pennies ( $18.64 - 0.43 = $18,21).
Sentiment: Strong Buy
Blackstone announced a quarterly distribution of 42 cents per unit payable on Feb 19 to stockholders of record as of Feb 11.
DOW JONES NEWSWIRES
A U.S. court has upheld a ruling awarding to PharmAthene Inc. (PIP) a portion of profits received by Siga Technologies Inc. (SIGA) from a smallpox drug, the latest development in the two companies' long-running legal battle.
PharmAthene, a government contractor that specializes in countering biological and chemical weapons, said the Delaware Court of Chancery issued a final judgement upholding a September decision. The court awarded PharmAthene a payment stream of 50% of the net profits that Siga receives from the next 10 years of sales of the drug, ST-246, after Siga receives all of its first $40 million of net profit.
"This decision brings this important phase of the litigation, which has been ongoing for over five years, to a positive close for PharmAthene shareholders," said President and Chief Executive Eric I. Richman.
Based on Siga's guidance expecting delivery of ST-246 to the U.S. government starting in the first quarter of 2013, PharmAthene expects a significant share of the revenue to accelerate profitability.
Siga, which specializes in developing drugs to fight biowarfare pathogens, wasn't immediately available for comment. It has said in the past that it disagrees with the court's ruling.
PharmAthene sued Siga in late 2006, alleging that it has the right to license exclusively development and marketing rights for ST-246. Siga had terminated a merger agreement with PharmAthene that October.
Siga shares closed at $2.31 on Thursday, and are down 8.3% so far this year. PharmAthene shares closed at $1.22 and are down 3.9%. Both were inactive in premarket trading
HOUSTON, Feb. 15, 2012 /PRNewswire via COMTEX/ -- Hyperdynamics Corporation (HDY) today announced that the Hyperdynamics-operated Sabu-1 exploration well reached the planned total depth of 11,844 feet in a water depth of 2,329 feet, approximately 90 miles southwest of Conakry, Guinea. The well encountered oil shows while drilling the targeted Upper Cretaceous section. Petrophysical analysis of electric logs indicates the presence of hydrocarbons in non-commercial concentrations in multiple layers of sandstones distributed throughout a 1,300-foot interval of Santonian to Turonian age sediments. The indicated oil saturation appears to be residual, suggesting that larger volumes of oil formerly were present in the reservoirs but subsequently leaked out or that these rocks lay on a hydrocarbon migration pathway.
"The Sabu-1 results provide evidence that hydrocarbon generation has taken place in the basin and enhances the prospectivity of our 9,650-square-mile concession, one of the largest in West Africa," commented Ray Leonard, Hyperdynamics' President and Chief Executive Officer. "The oil and sandstone reservoirs encountered in the Santonian and Turonian age sediments in the well are particularly encouraging in the development of the turbidite fan plays further down dip on the concession."
Hyperdynamics will be incorporating the results of the well, along with the interpretation of the newly acquired 4,000-square-kilometer 3D seismic survey that is currently being processed, in order to plan the subsequent drilling program in consultation with Dana Petroleum and the government of Guinea.
Orexigen(R) Therapeutics Presents Additional Contrave(R) Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
"The observation that patients in this sub-study maintained normal circadian variation of blood pressure may be particularly relevant since a loss of the nocturnal lowering in blood pressure may predict a poor cardiovascular outcome," said Jorge Plutzky, M.D., Director of the Vascular Disease Prevention Program at Brigham and Women's Hospital.
What does the "Poor Cardiovascular Outcome" mean ? Is it good or bad for OREX ?
How much BX would make ? if DYN shareholders vote NO to BX's takeover offer.
Just two months ago when the OIL was trading at around $80's, USO was trading at around $40s. Now Oil is trading at around $79, USO is still trading at around $35, can anybody explain me the reasons why USO is not trading at $40s.
Blackstone Group LP (BX) - reports Nov. 6. Wall Street Expectations: Analysts see third-quarter earnings of 15 cents a share on revenue of $450.6 million. A year earlier, Blackstone reported a loss of 44 cents a share on negative revenue of $229 million. (Negative revenue is possible, in part, because of accounting rules that require the company to mark the value of its holdings to current market prices.)